Drug intelligence / Profile preview

D930

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Administration: Ophthalmic

Overview

D930 is an investigational drug developed by Chong Kun Dang Pharmaceutical. It is being evaluated in clinical trials for the treatment of primary open-angle glaucoma and ocular hypertension. It has been studied in combination with D565 and as an active control against CKD-351 and Latanoprost. The drug is administered topically to the eye.

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on D930.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D930.

Explore the full profile